+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 21 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the pharmacokinetics, safety, and immune response of two drugs, RPH-030 and Vectibix4, in patients with metastatic colorectal cancer mCRC who have wild-type RAS genes. The study aims to show that these treatments are equivalent in how the body processes them and to compare their safety and immune effects. Additionally, the study will explore how effective these drugs are when used as first-line therapy combined with FOLFIRI chemotherapy. Participants will receive either RPH-030 or Vectibix4 intravenously at 6 mgkg every two weeks along with FOLFIRI chemotherapy, which includes irinotecan, calcium folinate, and fluorouracil. Treatment starts with FOLFIRI for 8 cycles, then continues with a modified de Gramont regimen. The study includes several periods a screening phase, a main period lasting up to 6 months, a continued therapy period up to 1 year where all patients receive RPH-030, and a treatment extension period lasting up to 2 years for patients with stable disease or response. Follow-up visits occur after treatment ends to monitor survival and disease status. Participants will undergo regular tumor assessments approximately every 6 to 8 weeks, hospitalizations for drug administration at specific visits, and blood sampling for pharmacokinetic and safety evaluations. Researchers will monitor drug levels over time, adverse events, immune reactions, and tumor responses. Follow-up includes imaging or phone calls to track overall survival and disease progression. The total study participation can last up to about 2 years with additional follow-up to ensure thorough monitoring of outcomes and safety.

Age: 18Years +All GendersPhase 1
26 locations
L

Actively Recruiting

This research aims to provide continued access to study treatments for participants with pulmonary hypertension who have completed previous clinical studies but have no other treatment alternatives. The study evaluates the long-term safety of these treatments, including macitentan, selexipag, and a fixed dose combination of macitentan and tadalafil. It is a phase 3, open-label study sponsored by Actelion. Participants who have completed parent studies and still benefit from their assigned treatment will continue receiving their study drug orally during this follow-up study. Adults typically take macitentan once daily, selexipag twice daily at their maintenance dose, or the macitentantadalafil combination once daily. Children aged 2 years and older receive doses adjusted by body weight. Study visits occur every 6 months for adults and every 3 months for pediatric participants, continuing until treatment becomes commercially available, an equivalent therapy is accessible, the participant withdraws, or the study ends early. During the study, participants undergo regular assessments to monitor safety and treatment effects, including collection of adverse event data, treatment discontinuations, serious adverse events, and deaths over up to 84 months. Visits include on-site evaluations of efficacy and safety. This long-term monitoring helps researchers understand the safety profile of these treatments when used beyond the initial clinical trials.

Age: 2Years +All GendersPhase 3
45 locations
O

Actively Recruiting

Researchers are conducting a large observational study involving 5,000 adult patients across about 50 regions in Russia who have uncontrolled severe asthma and are receiving standard treatments except biologic therapies. The study aims to better understand the characteristics, treatment patterns, and clinical outcomes of these patients, as there is currently limited data on this population in Russia. The study will not interfere with routine clinical care and is designed to collect comprehensive real-world information. Participants will have one study visit to gather demographic and clinical data without any additional diagnostic or therapeutic procedures beyond their usual care. This cross-sectional study will take place at 50 outpatient centers experienced in treating uncontrolled severe asthma, enrolling about 100 patients per region. The study will run from June 2024 to June 2027. During the single visit, researchers will collect information such as patients treatment regimens, use of oral corticosteroids, demographic details, clinical characteristics including comorbidities, lung function, and biomarkers like blood eosinophil counts and Immunoglobulin E levels. They will analyze these data to characterize treatment patterns and clinical outcomes in this population. No interventions are given, and patient safety is monitored through standard medical practice.

Age: 18Years +All Genders
40 locations
S

Actively Recruiting

Researchers are studying pediatric participants aged 4 weeks to less than 12 years with human immunodeficiency virus type 1 HIV-1 infection, weighing under 45 kg. The study focuses on treatment-naive children or those virologically suppressed on stable combination antiretroviral therapy for at least 3 months without treatment failure. The main goals are to evaluate the steady-state pharmacokinetics, safety, and tolerability of doravirine DOR when given with two nucleosidenucleotide reverse transcriptase inhibitors NRTIs or as part of the fixed-dose combination FDC of DORlamivudinetenofovir disoproxil fumarate DOR3TCTDF in children aged 6 to less than 12 years weighing 14 to less than 45 kg. Participants receive oral doravirine doses ranging from 7.2 mg to 100 mg based on weight, combined with two NRTIs according to local guidelines, or the fixed-dose combination DOR3TCTDF, for a treatment period of 96 weeks. Those completing the Week 96 visit may join an extension study to receive doravirine for up to an additional 224 weeks or until commercial availability. The study is open-label and conducted across multiple sites. During the study, participants undergo intensive pharmacokinetic sampling at designated times up to 24 hours postdose to measure doravirine levels in plasma. Researchers also monitor safety outcomes up to 24 weeks and additional secondary outcomes including viral load, CD4 T-cell counts, adverse events, adherence, and palatability of the oral pellets or granules. Assessments continue through Week 96, with close monitoring of viral suppression, drug resistance, and tolerability throughout the study and extension period.

Age: 4Weeks - 11YearsAll GendersPhase 2
26 locations
S

Actively Recruiting

The trial investigates the safety and effectiveness of olokizumab compared to a placebo in adults with progressive fibrosing interstitial lung diseases ILD. This phase 23 study uses a double-blind, parallel-group adaptive design to better understand treatment impacts on lung function over time. Participants have progressive fibrosing ILD confirmed by imaging and lung function tests, with disease progression documented within the prior months or years. Participants will be randomly assigned to receive either subcutaneous injections of olokizumab 64 mg or placebo every four weeks during a 48-week treatment period. The study includes a screening period lasting four weeks, followed by a treatment period of 48 weeks, and then a follow-up period of 24 weeks with visits scheduled at 4, 12, and 24 weeks post-treatment. The total duration of participation is approximately 76 weeks. Throughout the study, patients will undergo lung function tests including forced vital capacity FVC and diffusion capacity for carbon monoxide DLCO, as well as imaging assessments to evaluate lung fibrosis. Researchers will monitor symptoms, lung function changes, and quality of life measures using dyspnea scores and health questionnaires. Safety will be closely observed during treatment and follow-up visits, with the main outcome focused on changes in FVC over 48 weeks.

Age: 18Years +All GendersPhase 2Phase 3
33 locations
S

Actively Recruiting

Researchers are evaluating clinical outcomes for patients who begin inclisiran treatment within about two weeks after experiencing a heart attack STEMI or non-STEMI. This observational study focuses on patients in Russia and aims to understand the effects of inclisiran on lipid profiles, safety, atherosclerotic plaque status using carotid ultrasound, and the rates of hospitalizations and intensive follow-up over a 12-month period. Participants receive their first inclisiran injection approximately 14 days after their heart attack. The study observes changes in lipid levels at baseline, 3, 9, and 12 months, as well as plaque progression or regression over the year. Researchers also monitor adverse events, therapy discontinuation, hospital readmissions, emergency care visits, and the timing of dispensary observation. During the 12 months of participation, patients undergo lipid profile testing, carotid ultrasound scans, and safety evaluations at specified intervals. The main measure is the number of patients experiencing atherosclerotic cardiovascular disease events within a year after starting inclisiran in addition to their usual therapy. Secondary assessments include LDL cholesterol levels, plaque changes, adverse events, rehospitalizations, and use of emergency services, all tracked to evaluate the therapys impact and safety in real-world settings.

Age: 18Years - 100YearsAll Genders
18 locations
E

Actively Recruiting

Researchers are evaluating the use of ketamine infusion in subanesthetic doses as a neuroprotective method during the postoperative period in children undergoing surgery to correct congenital heart defects involving atrial or ventricular septal defects. The study aims to assess the safety and effectiveness of this approach in preventing brain injuries after these surgeries performed with cardiopulmonary bypass. Participants are randomly assigned to receive either ketamine infusion at doses of 0.1 mgkghour or 0.3 mgkghour for 16 hours, or no ketamine control group after their surgery. This intervention period focuses on the immediate postoperative phase to monitor ketamines impact on neuroprotection. During the study, children will undergo evaluations including biomarker measurements 16 hours after surgery to assess brain injury markers. Researchers will monitor safety and neuroprotective outcomes while following participants until study completion. The total participation duration aligns with the postoperative assessment period and study endpoints.

Age: 1Month - 5YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating how Lipoproteina Lpa levels vary among patients with Atherosclerotic Cardiovascular Disease ASCVD in Russia and investigating the relationship between elevated Lpa levels and cardiovascular disease risk. The study aims to better understand the distribution of Lpa and its connection to cardiovascular events in this population. The study includes several phases Phase I is a cross-sectional study measuring Lpa levels in ASCVD patients aged 18 and older. Phase II involves a non-interventional, prospective cohort study with these patients and their first-degree relatives, including parents and children with elevated Lpa levels. The study observes patients and relatives over time without altering their treatments. Participants will undergo assessments to measure Lpa levels and cardiovascular events at baseline and during follow-up visits up to 24 months. Researchers will collect clinical data, including disability status, cardiovascular events, hospitalizations, and lipid-lowering therapy usage. The study monitors the percentage of patients with elevated Lpa, occurrence of cardiovascular complications, and treatment outcomes to understand the impact of Lpa levels on ASCVD progression and related health events.

Age: 18Years - 99YearsAll Genders
20 locations
O

Actively Recruiting

Researchers are investigating the long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia HeFH or HoFH who have previously completed specific pediatric ORION studies. This open-label, single arm, multicenter extension study aims to provide continued access to inclisiran treatment while monitoring its effects over an extended period. Participants who completed the ORION-16 or ORION-13 studies receive a fixed dose of inclisiran sodium 300 mg in solution form. Those who completed ORION-19 or ORION-20 receive inclisiran doses adjusted based on their body weight. The study involves ongoing administration of inclisiran to assess long-term treatment outcomes. During the study, participants are monitored for adverse events and serious adverse events from the first day up to approximately 1080 days. Researchers measure changes in LDL cholesterol levels compared to baseline from the previous studies. Participants will have regular visits and assessments to track safety, tolerability, and lipid changes throughout the study duration, which may last up to nearly three years.

Age: 2Years - 100YearsAll GendersPhase 3
52 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a single bolus dose of non-immunogenic recombinant staphylokinase compared to a placebo in adults with intermediate high-risk pulmonary embolism PE who have stable blood pressure. This phase 3 trial addresses the need for safer thrombolytic treatments in patients who are at risk but do not have shock or low blood pressure, as previous thrombolytics had risks like hemorrhagic stroke. The study aims to improve outcomes while minimizing adverse effects in this patient group. Participants receive either a quick intravenous injection of non-immunogenic recombinant staphylokinase or a matching placebo. The staphylokinase dose is 15 mg given as a single bolus over 10-15 seconds regardless of body weight. The placebo group receives a similar injection with saline solution. This treatment period is followed by monitoring to compare the effects and safety between the two groups. During the study, participants will be assessed for clinical outcomes including death, hemodynamic collapse, and recurrent pulmonary embolism within 30 days. Additional measures include heart function and lung pressure evaluations within 24 hours and 30 days, along with monitoring for bleeding events and other adverse effects. The trial lasts for 30 days after treatment with ongoing safety checks, and participant consent and adherence to contraceptive use are required throughout the study period.

Age: 18Years +All GendersPhase 3
24 locations

1-10 of 21

1